I HAVE ALWAYS BEEN MOTIVATED BY THE IDEA THAT MY RESEARCH FINDINGS MIGHT BE TRANSLATED INTO REAL MEDICAL INNOVATION

DR BETHAN PSAILA

LAB282 helps to accelerate drug discovery in myelofibrosis.

Dr. Bethan Psaila is a haematology specialist with particular interest in mekacaryocyte biology and bone marrow disorders. She has more than 20 high-ranking publications to her name*, and is a close collaborator in the lab of Prof. Adam Mead.

Having successfully used state-of-the-art technologies, including single-cell sequencing, to identify potential targets for myelofibrosis, a severe bone marrow disorder, Bethan was seeking to collaborate with an expert organization such as Evotec to prioritize target candidates. Following exploratory discussions, she applied for a small-scale LAB282 award which was granted.

Experiments to validate her target hypothesis -including utilization of Evotec’s proprietary bioinformatics platform as well as in vitro experiments with small molecule tool compounds to the target candidates in question- have been successfully concluded, giving the opportunity to roll-over from a small-scale to a large-scale award.

“I have always been motivated by the idea that my research findings might be translated into real medical innovation that makes meaningful differences to patients with blood cancers. With LAB282, we now have access to a world-class drug discovery platform that can help accelerate this process.”

* KEY RECENT PUBLICATION

Single-cell profiling of human megakaryocyte-erythroid progenitors identifies distinct megakaryocyte and erythroid differentiation pathways. Psaila B, et al Genome Biology 2016 May 3; 17:83

Lab282 Partners